Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula
Information source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid (Drug); Aeroneb Solo (Device); Jet Nebulizer (Device); Single photon emission computed tomography (Other); Spirometry (Other)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Summary
Vibrating-mesh nebulizers ensure currently the best deposition output and are recommended in
routine use in intensive care unit. However, jet nebulizers remain the most frequently used
nebulizers.
On a bench study, aerosol delivery through a high flow nasal cannula (HFNC) was increased
using a vibrating-mesh nebulizer as compared to a jet nebulizer.
Lung distribution of nebulized particles delivered through a HFNC has never been
investigated in vivo. The aim of this study was to compare aerosol lung distribution with
both nebulizers through a HFNC by SPECT-CT.
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)
Primary outcome: Pulmonary deposition
Secondary outcome: Three-dimensional penetration index
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy respiratory function
Exclusion Criteria:
- Pulmonary disease
Locations and Contacts
Cliniques Universitaires Saint-Luc, Brussels 1200, Belgium
Additional Information
Starting date: April 2015
Last updated: April 24, 2015
|